Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Immerge BioTherapeutics announces identification of PERV receptor

27.05.2003


Important step forward for safety of xenotransplantation



This week in the Proceedings of the National Academy of Sciences, researchers from Immerge BioTherapeutics, Inc., announced that they have identified the receptors that are used by porcine endogenous retrovirus (PERV) in order to enter and infect a cell (PNAS; May 27, 2003; vol. 100, no. 11; 6759-6764). This is a critical discovery because it allows scientists to begin to develop strategies to prevent PERV replication. PERV has been considered a key safety issue in the development of xenotransplantation using pig organs because the virus has shown the ability to infect some human cells in laboratory tissue cultures. The study was performed in a collaborative effort between Immerge and the academic groups of Professors Robin Weiss, University College, London, UK and Daniel Salomon, The Scripps Research Institute, La Jolla, CA.

"Our identification of the PERV receptor is a major step forward because it allows us to address fundamental aspects of the biology of this virus," said Dr Clive Patience, Director of the Safety Program at Immerge. "For instance, PERV has grown in only three of approximately 40 human cell lines that we and others have tested. To date, we have not understood why most human cells do not support PERV growth. We can now begin to address this type of fundamental issue."


PERV is a virus that all pigs are born with, which poses no harm to the pig itself. However, unlike other viruses, which can be eliminated either through breeding or raising pigs in a clean lab environment, multiple copies of PERV form part of the normal genomic DNA of pigs and are therefore passed from one generation to the next.

"PERV is of concern in developing xenotransplantation of porcine organs towards an accepted procedure in clinical medicine," commented Professor Robin Weiss from University College, London. "We need to understand the basic virology of PERV, and indeed other porcine microorganisms, before xenotransplantation can be considered a safe procedure."

There is a critical need to identify new sources of organs for the growing number of people needing life-saving transplants around the world. In the U.S. alone, there are more than 81,000 people on the waiting list for organs and an unknown number of additional people needing organs who did not qualify for the transplant list because of age, illness or other issues.

"There is an unmet need in clinical transplantation for donors, and the availability of acceptable porcine organs could solve this huge demand" said Professor Dan Salomon from The Scripps Research Institute. "It remains important to identify the risk of a potentially infectious agent to both the patient receiving a transplant as well as others. Our identification of the PERV receptors will allow us to begin to address this issue."

As part of its progress toward clinical xenotransplantation, Immerge BioTherapeutics Inc. has developed a safety program with a number of international expert collaborators. The depth of Immerge’s safety program is unique among companies conducting xenotransplantation research. The company has previously reported the identification of animals within its miniature swine herd that do not transmit PERV to human cell lines (Oldmixon et al. Journal of Virology 2002; 76: 3045-3048). In the past year, in collaborative efforts with the University of Missouri-Columbia and Infigen, Inc., Immerge also announced the birth of cloned, double knock-out miniature swine that lack expression of the GGTA1 gene. This gene is responsible for rapid rejection of organs and makes the animal organs more compatible for potential human transplant.


Immerge BioTherapeutics was formed on September 26, 2000, as a joint venture between Novartis Pharma AG and BioTransplant Incorporated. The company, which began operations on January 2, 2001, focuses its research efforts toward developing therapeutic applications for xenotransplantation.

Susan Hayes | EurekAlert!

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>